Skip to content

Compared Efficacy of Nurse-led and GP-led Geriatric Assessment in PrImary Care

Compared Efficacy of Nurse-led and GP-led Geriatric Assessment in PrImary Care: A Pragmatic Three-arm Cluster Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02664454
Acronym
CEPIA
Enrollment
750
Registered
2016-01-27
Start date
2016-05-24
Completion date
2018-08-24
Last updated
2024-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Geriatric Assessment, Multimorbidity

Keywords

Elderly, Health care organization, Primary care

Brief summary

Older patients account for around 10% of the population, of which 57% have a long-term illness, and 33% were admitted in the past year. Geriatric assessment (GA) is a multidimensional assessment of general health status that can help identifying deficiencies and followed by a personalized care plan. Assessment and management of elderly patients is a daily concern for the general practitioner (GP) but conflicting results have been reported so far relating to the clinical impact of GA when applied in the primary care setting. This study protocol aims to assess the effect on morbi-mortality of a complex intervention in patients aged ≥70 years with chronic conditions in primary care. It aims to demonstrate that a GA adapted to primary care, followed by a personalized care plan and combined with successful interprofessional collaboration can improve clinically relevant outcomes in elderly patients with chronic conditions such as one-year overall mortality, unplanned hospital admission, emergency visits, or institutionalization. The CEPIA study will also help addressing the issue of whether an improved benefit could be achieved from a systematic nurse-led or a case-by-case GP-led GA.

Interventions

OTHERhealth care organization

Nurse-led or GP-led Geriatric assessment combined with an educational seminar focused on GA and personalized care-plan as well as a dedicated hotline for general practitioners seeking a geriatric advice Interactive educational seminar Primary care

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
70 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients aged≥70 years with a long-term illness scheme or hospital admission the past 3 months * Visiting their preferred general practioner (GP) or another GP in the same practice * patient oral non opposition

Exclusion criteria

* Patient who does not speak French * Severe disease with a life expectancy \<12 months * Institutionalized patients * Patient insured under the French national health insurance system

Design outcomes

Primary

MeasureTime frame
Primary composite endpoint combined with: - Percentage of all-cause mortality - Percentage of Unplanned hospital admission - Percentage of Emergency visits. - Percentage of InstitutionalizationAt 12 months

Secondary

MeasureTime frameDescription
Percentage of Unplanned hospital admissionAt 12 months
Percentage of Emergency visitsAt 12 months
Percentage of InstitutionalizationAt 12 months
Quality of life (Duke profile score)At Day 0 and 12 months
Autonomy by KATZ ALD scoreAt Day 0 and 12 months
Number of medication prescription (polypharmacy)Up to 12 months
Percentage of all-cause mortalityAt 12 months
Percentage of personalized care plan performedUp to 12 months
Percentage of geriatric phone advices requested by GPsUp to 12 months
Percentage of health care actions plannedUp to 12 months
Percentage of satisfied general practitioner with the intervention27months after the beginning of the studyself-assessment
Satisfaction of general practitioners and nurses after completion of intervention12 months after the beginning of the studyinterview of general practionners and nurses by independant investigator
Percentage of Geriatric assessment performedUp to 12 months

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026